Items Tagged with 'Pfizer'
SubscribeARTICLES
Updates for May 2013: Purchase Price Raised for Pfizer and J&J
Pfizer Completes Sale of Nutrition Business to Nestlé
On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.
Pfizer Reports Third-Quarter 2012 Results
On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.
Pfizer Second Quarter Financials Released
On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.
Pfizer FDA Approval Received
On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
Pfizer Financials Announced
On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.
Pfizer and Nestle Nutrition Business Agreement Announced
On April 23, 2012, Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement to divest its Nutrition business to Nestle for $11.85 billion in cash.
Pfizer Acquisition Announced
On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....
Pfizer Recall Announced
On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.
Pfizer FDA Approval Received
On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Profit from The Turnaround Letter's...
- Market-Beating Investment Results
- 25+ Years of Turnaround Experience
- Diverse Stock Picks for Today's Unpredictable Market
TLCorner
Time to Pay the Piper: 7 Strategies to Minimize Tax Pain
Europe’s Not Out of the Woods Yet, But…
What did The Turnaround Letter see that others did not?
Questions & Tips
AskGeorge
Why are you still recommending MGIC?
I don’t normally comment on individual stocks in this particular blog, but the MGIC situation represents a basic investment principle that is worthy of discussion here.
Read More.How important are Price-to-Earnings (P/E) ratios in evaluating turnaround stocks?
Price-to-Earnings ratios are probably the most widely used tool for comparing the relative values of different stocks.
Read More.Does the poor performance of the stock market in May indicate that the U.S. is headed for a new recession?
This question comes up frequently when the market takes a dip.
Read More.
